Kanjinti (trastuzumab-anns) PDUFA Date (Amgen Inc)
FDA PDUFA decision date for Kanjinti (trastuzumab-anns) is December 19, 2024. Developed by Amgen Inc. Indication: HER2/neu Receptor Antagonist [EPC]. Current status: Approved.
Indication
HER2/neu Receptor Antagonist [EPC]
Regulatory details
- Company: Amgen Inc
- Application type: sBLA
- Review type: Standard
- PDUFA date: 2024-12-19
- Outcome: Approved